A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.
Latest Information Update: 22 Sep 2025
At a glance
- Drugs Trastuzumab rezetecan (Primary) ; Trastuzumab rezetecan (Primary)
- Indications HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 22 Sep 2025 New trial record